Satellos Bioscience Inc (MSLE) FinancialsMSLESatellos Bioscience Inc

Evaluating the bottom line, Satellos Bioscience Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -70.45%, provide a clear picture of how effectively MSLE converts its operational activities into shareholder value.

In the context of the broader market, MSLE competes directly with industry leaders such as PALI and PRQR. With a market capitalization of $134.75M, it holds a significant position in the sector. When comparing efficiency, MSLE's gross margin of N/A stands against PALI's 100.00% and PRQR's 100.00%. Such benchmarking helps identify whether Satellos Bioscience Inc. is trading at a premium or discount relative to its financial performance.

Satellos has reported significant net losses, with the latest quarterly net income at -9,768,000 USD and a negative EPS of -0.56. The company has a forward P/E of 0, indicating no earnings expected in the near term, and a current ratio of 11.22, showing good liquidity.